Monoclonal Antibody Therapy in Lymphoid Malignancies

Monoclonal Antibody Therapy in Lymphoid Malignancies John D. Hainsworth Oncologist 2000; 5: 376-384 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine regarding lymphomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Understand the role of rituximab in the treatment of indolent non-Hodgkin's lymphomas. Identify the potential acute toxicities of rituximab. Appreciate the emerging roles of other new target agents, including Campath-1H, Bexxar, and Zevalin. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 16, 2005 Most Recent Review: Mar. 16, 2005* Most Recent Update: Mar. 16, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.